Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1979 2
1980 2
1981 5
1982 5
1983 5
1984 5
1985 3
1986 3
1987 2
1989 3
1990 1
1991 8
1992 5
1993 3
1994 4
1995 1
1996 4
1997 3
1998 6
1999 2
2000 3
2001 5
2002 8
2003 5
2004 6
2005 7
2006 7
2007 5
2008 7
2009 8
2010 6
2011 7
2012 8
2013 9
2014 5
2015 4
2016 3
2017 2
2018 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Among authors: laplanche a. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.
Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T. Neuzillet Y, et al. Among authors: laplanche a. Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461580 French. No abstract available.
Alcohol-attributable mortality in France.
Guérin S, Laplanche A, Dunant A, Hill C. Guérin S, et al. Among authors: laplanche a. Eur J Public Health. 2013 Aug;23(4):588-93. doi: 10.1093/eurpub/ckt015. Epub 2013 Mar 4. Eur J Public Health. 2013. PMID: 23460733
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F. Rebouissou S, et al. Among authors: laplanche a. Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970. Sci Transl Med. 2014. PMID: 25009231
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Gross-Goupil M, et al. Among authors: laplanche a. Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Epub 2012 Feb 6. Eur J Cancer. 2012. PMID: 22317952 Review.
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F. Vallot C, et al. Among authors: laplanche a. J Natl Cancer Inst. 2011 Jan 5;103(1):47-60. doi: 10.1093/jnci/djq470. Epub 2010 Dec 20. J Natl Cancer Inst. 2011. PMID: 21173382 Free PMC article.
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K. Loriot Y, et al. Among authors: laplanche a. Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29149760 Clinical Trial.
169 results